Brainstorm Cell Therapeutics Stock Price, News & Analysis (NASDAQ:BCLI)

$3.16 -0.01 (-0.32 %)
(As of 02/20/2018 02:58 AM ET)
Previous Close$3.16
Today's Range$3.13 - $3.23
52-Week Range$2.88 - $5.18
VolumeN/A
Average Volume54,350 shs
Market Capitalization$59.54 million
P/E Ratio-10.19
Dividend YieldN/A
Beta1.32

About Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Brainstorm Cell Therapeutics logoBrainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.

Receive BCLI News and Ratings via Email

Sign-up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:BCLI
CUSIPN/A
Phone+1-201-4880460

Debt

Debt-to-Equity RatioN/A
Current Ratio1.78%
Quick Ratio1.78%

Price-To-Earnings

Trailing P/E Ratio-10.1935483870968
Forward P/E Ratio-8.54
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.53 per share
Price / Book5.96

Profitability

Trailing EPS($0.31)
Net Income$-4,980,000.00
Net MarginsN/A
Return on Equity-76.45%
Return on Assets-59.84%

Miscellaneous

Employees22
Outstanding Shares18,840,000

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Frequently Asked Questions

What is Brainstorm Cell Therapeutics' stock symbol?

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) issued its quarterly earnings data on Monday, August, 14th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.04. View Brainstorm Cell Therapeutics' Earnings History.

When will Brainstorm Cell Therapeutics make its next earnings announcement?

Brainstorm Cell Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March, 29th 2018. View Earnings Estimates for Brainstorm Cell Therapeutics.

Where is Brainstorm Cell Therapeutics' stock going? Where will Brainstorm Cell Therapeutics' stock price be in 2018?

1 Wall Street analysts have issued twelve-month price objectives for Brainstorm Cell Therapeutics' stock. Their forecasts range from $9.00 to $9.00. On average, they anticipate Brainstorm Cell Therapeutics' stock price to reach $9.00 in the next twelve months. View Analyst Ratings for Brainstorm Cell Therapeutics.

Who are some of Brainstorm Cell Therapeutics' key competitors?

Who are Brainstorm Cell Therapeutics' key executives?

Brainstorm Cell Therapeutics' management team includes the folowing people:

  • Irit Arbel, Independent Chairman of the Board (Age 57)
  • Chaim Lebovits, President, Chief Executive Officer (Age 46)
  • Eyal Rubin, Chief Financial Officer, Treasurer (Age 42)
  • Ralph Kern, Chief Operating Officer and Chief Medical Officer (Age 60)
  • Uri Yablonka, Executive Vice President, Chief Business Officer, Director (Age 40)
  • Chen Schor CPA, Director (Age 44)
  • June S. Almenoff M.D. Ph.D., Independent Director (Age 60)
  • Arturo O. Araya, Independent Director (Age 47)
  • Mordechai Friedman, Independent Director (Age 65)
  • Alon Pinkas, Independent Director (Age 56)

Who owns Brainstorm Cell Therapeutics stock?

Brainstorm Cell Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.61%), Deutsche Bank AG (0.52%) and Clearline Capital LP (0.28%). Company insiders that own Brainstorm Cell Therapeutics stock include Irit Arbel and Uri Yablonka. View Institutional Ownership Trends for Brainstorm Cell Therapeutics.

Who bought Brainstorm Cell Therapeutics stock? Who is buying Brainstorm Cell Therapeutics stock?

Brainstorm Cell Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Deutsche Bank AG and Clearline Capital LP. Company insiders that have bought Brainstorm Cell Therapeutics stock in the last two years include Irit Arbel and Uri Yablonka. View Insider Buying and Selling for Brainstorm Cell Therapeutics.

How do I buy Brainstorm Cell Therapeutics stock?

Shares of Brainstorm Cell Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Brainstorm Cell Therapeutics' stock price today?

One share of Brainstorm Cell Therapeutics stock can currently be purchased for approximately $3.16.

How big of a company is Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics has a market capitalization of $59.54 million. The biotechnology company earns $-4,980,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis. Brainstorm Cell Therapeutics employs 22 workers across the globe.

How can I contact Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics' mailing address is 3 University Plaza Drive, Suite 320, HACKENSACK, NJ 07601, United States. The biotechnology company can be reached via phone at +1-201-4880460 or via email at [email protected]


MarketBeat Community Rating for Brainstorm Cell Therapeutics (BCLI)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  123 (Vote Outperform)
Underperform Votes:  74 (Vote Underperform)
Total Votes:  197
MarketBeat's community ratings are surveys of what our community members think about Brainstorm Cell Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.00$9.00$9.00$9.00
Price Target Upside: 204.05% upside204.05% upside122.77% upside115.31% upside

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Consensus Price Target History

Price Target History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/27/2017Maxim GroupSet Price TargetBuy$9.00MediumView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earnings History and Estimates Chart

Earnings by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Brainstorm Cell Therapeutics (NASDAQ BCLI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/28/2018($0.27)N/AView Earnings Details
10/17/2017Q3 2017($0.16)($0.13)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.10)($0.06)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.30)($0.10)ViewN/AView Earnings Details
3/30/2017Q4 2016($0.07)($0.03)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.11)($0.09)ViewN/AView Earnings Details
8/11/2016Q2($0.18)($0.05)ViewN/AView Earnings Details
5/10/2016Q116($0.25)($0.10)ViewN/AView Earnings Details
3/10/2016Q415($0.15)($0.07)ViewN/AView Earnings Details
11/17/2015Q3($0.14)($0.14)ViewN/AView Earnings Details
8/13/2015Q215($0.13)($0.12)ViewListenView Earnings Details
5/14/2015Q115($0.14)($0.12)ViewListenView Earnings Details
3/26/2015Q414($0.18)($0.18)ViewN/AView Earnings Details
11/13/2014($0.12)($0.16)ViewN/AView Earnings Details
11/13/2014Q3 14($0.12)($0.16)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.37 EPS
Next Year EPS Consensus Estimate: $-0.42 EPS

Dividends

Dividend History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Brainstorm Cell Therapeutics (NASDAQ BCLI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 24.70%
Institutional Ownership Percentage: 8.82%
Insider Trades by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Institutional Ownership by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Brainstorm Cell Therapeutics (NASDAQ BCLI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/31/2017Irit ArbelDirectorBuy2,500$4.26$10,650.00155,833View SEC Filing  
8/23/2017Uri YablonkaEVPBuy2,000$3.98$7,960.007,543View SEC Filing  
12/16/2015Robert G L ShorrDirectorSell10,800$2.71$29,268.0028,399View SEC Filing  
12/15/2015Malcolm S. TaubDirectorSell41,742$2.60$108,529.208,666View SEC Filing  
12/11/2015Malcolm S. TaubDirectorSell13,480$2.73$36,800.4050,408View SEC Filing  
10/1/2015International Holdings Ltd AccMajor ShareholderBuy2,000$2.58$5,160.00138,806View SEC Filing  
9/30/2015International Holdings Ltd AccMajor ShareholderBuy9,200$2.34$21,528.00136,806View SEC Filing  
8/20/2015Yoram BibringCFOBuy8,500$3.04$25,840.0050,000View SEC Filing  
8/17/2015Yoram BibringCFOBuy41,500$2.92$121,180.00View SEC Filing  
10/10/2014International Holdings Ltd AccMajor ShareholderBuy8,600$4.06$34,916.00View SEC Filing  
10/1/2014International Holdings Ltd AccMajor ShareholderBuy6,700$4.14$27,738.00View SEC Filing  
9/22/2014International Holdings Ltd AccMajor ShareholderBuy11,000$4.17$45,870.00View SEC Filing  
9/15/2014Anthony S FiorinoCEOBuy18,000$0.28$5,040.00View SEC Filing  
6/16/2014International Holdings Ltd AccMajor ShareholderBuy130,000$0.29$37,700.00View SEC Filing  
6/13/2014International Holdings Ltd AccMajor ShareholderBuy150,000$0.35$52,500.00View SEC Filing  
4/28/2014International Holdings Ltd AccMajor ShareholderBuy939,600$0.30$281,880.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Brainstorm Cell Therapeutics (NASDAQ BCLI) News Headlines

Source:
DateHeadline
ALS patients are unhappy with how $115 million raised by the Ice Bucket Challenge is being spentALS patients are unhappy with how $115 million raised by the Ice Bucket Challenge is being spent
finance.yahoo.com - February 14 at 9:43 AM
Corvus Pharmaceuticals (CRVS) versus Brainstorm Cell Therapeutics (BCLI) Head-To-Head ReviewCorvus Pharmaceuticals (CRVS) versus Brainstorm Cell Therapeutics (BCLI) Head-To-Head Review
www.americanbankingnews.com - February 11 at 8:10 AM
Brainstorm Cell Therapeutics (BCLI) Names Anthony Polverino PhD ... - StreetInsider.comBrainstorm Cell Therapeutics (BCLI) Names Anthony Polverino PhD ... - StreetInsider.com
www.streetinsider.com - February 5 at 3:40 PM
Brainstorm Cell Therapeutics (BCLI) Names Anthony Polverino PhD ... - StreetInsider.comBrainstorm Cell Therapeutics (BCLI) Names Anthony Polverino PhD ... - StreetInsider.com
www.streetinsider.com - February 5 at 3:40 PM
Brainstorm Cell Therapeutics (BCLI) Names Anthony Polverino PhD to BoardBrainstorm Cell Therapeutics (BCLI) Names Anthony Polverino PhD to Board
www.streetinsider.com - February 5 at 9:34 AM
BrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of DirectorsBrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of Directors
finance.yahoo.com - February 5 at 9:34 AM
Brainstorm Cell Therapeutics (BCLI) versus Its Peers Critical ComparisonBrainstorm Cell Therapeutics (BCLI) versus Its Peers Critical Comparison
www.americanbankingnews.com - January 12 at 1:18 AM
Analyzing Brainstorm Cell Therapeutics (BCLI) and Its CompetitorsAnalyzing Brainstorm Cell Therapeutics (BCLI) and Its Competitors
www.americanbankingnews.com - January 9 at 1:42 PM
-$0.09 EPS Expected for Brainstorm Cell Therapeutics Inc (BCLI) This Quarter-$0.09 EPS Expected for Brainstorm Cell Therapeutics Inc (BCLI) This Quarter
www.americanbankingnews.com - January 5 at 5:28 AM
BCLI: Receives GMP Certification for NurOwn® Manufacturing Facility; Ready to Seek Approval Under Hospital Exemption in IsraelBCLI: Receives GMP Certification for NurOwn® Manufacturing Facility; Ready to Seek Approval Under Hospital Exemption in Israel
finance.yahoo.com - January 4 at 3:24 PM
BrainStorm Granted GMP Certification for a Marketing-Level Manufacturing of NurOwn®BrainStorm Granted GMP Certification for a Marketing-Level Manufacturing of NurOwn®
finance.yahoo.com - January 3 at 11:06 AM
Analysts Anticipate Brainstorm Cell Therapeutics Inc (BCLI) to Post ($0.09) EPSAnalysts Anticipate Brainstorm Cell Therapeutics Inc (BCLI) to Post ($0.09) EPS
www.americanbankingnews.com - December 29 at 11:30 PM
Brainstorm Cell Therapeutics (BCLI) Upgraded to "Hold" at ValuEngineBrainstorm Cell Therapeutics (BCLI) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - December 29 at 9:26 PM
Brainstorm Issues 2017 Letter to ShareholdersBrainstorm Issues 2017 Letter to Shareholders
finance.yahoo.com - December 29 at 9:26 AM
Brainstorm Cell Therapeutics (BCLI) PT Set at $9.00 by Maxim GroupBrainstorm Cell Therapeutics (BCLI) PT Set at $9.00 by Maxim Group
www.americanbankingnews.com - December 27 at 4:10 PM
Brainstorm Cell Therapeutics (BCLI) Lowered to Sell at ValuEngineBrainstorm Cell Therapeutics (BCLI) Lowered to Sell at ValuEngine
www.americanbankingnews.com - December 21 at 11:26 PM
BrainStorm Cell Therapeutics to Present at the 10th Annual Biotech ... - PR Newswire (press release)BrainStorm Cell Therapeutics to Present at the 10th Annual Biotech ... - PR Newswire (press release)
www.prnewswire.com - December 20 at 7:47 AM
BrainStorm Cell Therapeutics to Present at the 10th Annual Biotech ShowcaseBrainStorm Cell Therapeutics to Present at the 10th Annual Biotech Showcase
finance.yahoo.com - December 20 at 7:47 AM
Brainstorm Cell Therapeutics (BCLI) versus The Competition Head-To-Head ReviewBrainstorm Cell Therapeutics (BCLI) versus The Competition Head-To-Head Review
www.americanbankingnews.com - December 20 at 7:14 AM
-$0.09 Earnings Per Share Expected for Brainstorm Cell Therapeutics Inc (BCLI) This Quarter-$0.09 Earnings Per Share Expected for Brainstorm Cell Therapeutics Inc (BCLI) This Quarter
www.americanbankingnews.com - December 19 at 7:08 PM
Reviewing Brainstorm Cell Therapeutics (BCLI) & Its RivalsReviewing Brainstorm Cell Therapeutics (BCLI) & Its Rivals
www.americanbankingnews.com - December 16 at 11:08 PM
Brainstorm Cell Therapeutics Inc. (BCLI) Expected to Post Earnings of -$0.09 Per ShareBrainstorm Cell Therapeutics Inc. (BCLI) Expected to Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - December 1 at 11:34 PM
Zacks: Brainstorm Cell Therapeutics Inc. (BCLI) Given $12.00 Average Target Price by AnalystsZacks: Brainstorm Cell Therapeutics Inc. (BCLI) Given $12.00 Average Target Price by Analysts
www.americanbankingnews.com - December 1 at 7:30 PM
Brainstorm (BCLI) Says Abstracts on Phase 2 NurOwn Biomarkers Accepted for Presentation at International Symposium on ALS/MNDBrainstorm (BCLI) Says Abstracts on Phase 2 NurOwn Biomarkers Accepted for Presentation at International Symposium on ALS/MND
www.streetinsider.com - November 29 at 3:23 PM
Brainstorm (BCLI) Says Abstracts on Phase 2 NurOwn Biomarkers ... - StreetInsider.comBrainstorm (BCLI) Says Abstracts on Phase 2 NurOwn Biomarkers ... - StreetInsider.com
www.streetinsider.com - November 29 at 7:58 AM
BrainStorms Abstracts on Phase 2 NurOwn® Biomarkers Accepted for Presentation at the International Symposium on ALS/MND in BostonBrainStorm's Abstracts on Phase 2 NurOwn® Biomarkers Accepted for Presentation at the International Symposium on ALS/MND in Boston
finance.yahoo.com - November 29 at 7:58 AM
Zacks: Brokerages Anticipate Brainstorm Cell Therapeutics Inc. (BCLI) to Announce -$0.09 Earnings Per ShareZacks: Brokerages Anticipate Brainstorm Cell Therapeutics Inc. (BCLI) to Announce -$0.09 Earnings Per Share
www.americanbankingnews.com - November 13 at 7:30 PM
AEterna Zentaris (AEZS) & Brainstorm Cell Therapeutics (BCLI) Financial ReviewAEterna Zentaris (AEZS) & Brainstorm Cell Therapeutics (BCLI) Financial Review
www.americanbankingnews.com - October 28 at 3:04 AM
FDA Approves New Use For Soliris, HSTM In Good Health, BYSI Springs A Surprise - NasdaqFDA Approves New Use For Soliris, HSTM In Good Health, BYSI Springs A Surprise - Nasdaq
www.nasdaq.com - October 24 at 3:26 AM
BrainStorm Expands Its Patent Portfolio to Include a New US Patent ... - PR Newswire (press release)BrainStorm Expands Its Patent Portfolio to Include a New US Patent ... - PR Newswire (press release)
www.prnewswire.com - October 24 at 3:26 AM
BrainStorm nabs new patent covering NurOwn; shares ahead 4%BrainStorm nabs new patent covering NurOwn; shares ahead 4%
seekingalpha.com - October 23 at 5:22 PM
BrainStorm Expands Its Patent Portfolio to Include a New US Patent For Its NurOwn® Technology for Parkinsons Disease And ALSBrainStorm Expands Its Patent Portfolio to Include a New US Patent For Its NurOwn® Technology for Parkinson's Disease And ALS
finance.yahoo.com - October 23 at 5:22 PM
Corporate News Blog - Novan Acquires Intellectual Property Rights for Treating Viral Malignancies with Nitric OxideCorporate News Blog - Novan Acquires Intellectual Property Rights for Treating Viral Malignancies with Nitric Oxide
finance.yahoo.com - October 20 at 6:10 PM
Brainstorm Cell Therapeutics Inc. (BCLI) to Post FY2017 Earnings of ($0.37) Per Share, Zacks Investment Research ForecastsBrainstorm Cell Therapeutics Inc. (BCLI) to Post FY2017 Earnings of ($0.37) Per Share, Zacks Investment Research Forecasts
www.americanbankingnews.com - October 20 at 12:16 PM
BrainStorm Cell Therapeutics (BCLI) CEO Chaim Lebovits on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaBrainStorm Cell Therapeutics' (BCLI) CEO Chaim Lebovits on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - October 17 at 10:20 PM
BrainStorm Cell Therapeutics reports Q3 resultsBrainStorm Cell Therapeutics reports Q3 results
seekingalpha.com - October 17 at 5:17 PM
BrainStorm Announces Third Quarter 2017 Financial ResultsBrainStorm Announces Third Quarter 2017 Financial Results
finance.yahoo.com - October 17 at 5:17 PM
BCLI: Initiates Phase 3 Clinical Trial of NurOwn® in ALSBCLI: Initiates Phase 3 Clinical Trial of NurOwn® in ALS
finance.yahoo.com - October 17 at 5:17 PM
Brainstorm Cell Therapeutics Inc. (BCLI) Announces  Earnings Results, Beats Estimates By $0.03 EPSBrainstorm Cell Therapeutics Inc. (BCLI) Announces Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - October 17 at 8:46 AM
Brainstorm Cell Therapeutics Inc. (BCLI) Given a $9.00 Price Target at Maxim GroupBrainstorm Cell Therapeutics Inc. (BCLI) Given a $9.00 Price Target at Maxim Group
www.americanbankingnews.com - October 16 at 12:58 PM
BrainStorm enrolls first patients in advanced ALS stem cell trialBrainStorm enrolls first patients in advanced ALS stem cell trial
finance.yahoo.com - October 16 at 2:11 AM
BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn® in ALSBrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn® in ALS
finance.yahoo.com - October 16 at 2:11 AM
Brainstorm Cell Therapeutics Inc. (BCLI) Scheduled to Post Quarterly Earnings on TuesdayBrainstorm Cell Therapeutics Inc. (BCLI) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 10 at 2:16 AM
Reviewing Cara Therapeutics (CARA) and Brainstorm Cell Therapeutics (BCLI)Reviewing Cara Therapeutics (CARA) and Brainstorm Cell Therapeutics (BCLI)
www.americanbankingnews.com - October 5 at 4:48 PM
Zacks: Brokerages Anticipate Brainstorm Cell Therapeutics Inc. (BCLI) to Post -$0.10 Earnings Per ShareZacks: Brokerages Anticipate Brainstorm Cell Therapeutics Inc. (BCLI) to Post -$0.10 Earnings Per Share
www.americanbankingnews.com - October 5 at 9:22 AM
Brainstorm to Announce Third Quarter Financial Results And Provide Corporate Updates on Tuesday, October 17Brainstorm to Announce Third Quarter Financial Results And Provide Corporate Updates on Tuesday, October 17
finance.yahoo.com - October 3 at 4:13 PM
Head-To-Head Survey: Quintiles IMS Holdings (Q) versus Brainstorm Cell Therapeutics (BCLI)Head-To-Head Survey: Quintiles IMS Holdings (Q) versus Brainstorm Cell Therapeutics (BCLI)
www.americanbankingnews.com - October 1 at 4:34 AM
BrainStorm Cell Therapeutics to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by ... - PR Newswire (press release)BrainStorm Cell Therapeutics to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by ... - PR Newswire (press release)
www.prnewswire.com - September 29 at 8:46 AM
BrainStorm Cell Therapeutics to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by SeeThruEquity and RHK CapitalBrainStorm Cell Therapeutics to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by SeeThruEquity and RHK Capital
finance.yahoo.com - September 27 at 7:39 PM
Brainstorm Cell Therapeutics (BCLI) vs. Palatin Technologies (PTN) Head to Head ReviewBrainstorm Cell Therapeutics (BCLI) vs. Palatin Technologies (PTN) Head to Head Review
www.americanbankingnews.com - September 21 at 4:26 PM

SEC Filings

Brainstorm Cell Therapeutics (NASDAQ:BCLI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Brainstorm Cell Therapeutics (NASDAQ BCLI) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.